(Q40693727)

22 September 2017

1 reference

title

Interferon beta for multiple sclerosis (English)

1 reference

22 September 2017

J F Connelly

1

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

Annals of Pharmacotherapy

22 September 2017

published in

1 reference

22 September 2017

volume

28

1 reference

22 September 2017

issue

5

1 reference

22 September 2017

page(s)

610-616

1 reference

Immunotherapy of multiple sclerosis

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Immunosuppressive treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Interferons in multiple sclerosis. A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Genetic factors in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Clinical viral infections and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Interferons and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Multiple sclerosis: involvement of interferons in lesion pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Biological and clinical effects of interferon-beta ser at two doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Persistent neurotoxicity of systemically administered interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Systemic alpha-interferon therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Intrathecal interferon in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Intrathecal interferon in the treatment of multiple sclerosis. Patient follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809402800511

10.1177/106002809402800511

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference